ATE359807T1 - Modifizierte annexin-proteine und verhinderung und behandlung von thrombose - Google Patents
Modifizierte annexin-proteine und verhinderung und behandlung von thromboseInfo
- Publication number
- ATE359807T1 ATE359807T1 AT02721083T AT02721083T ATE359807T1 AT E359807 T1 ATE359807 T1 AT E359807T1 AT 02721083 T AT02721083 T AT 02721083T AT 02721083 T AT02721083 T AT 02721083T AT E359807 T1 ATE359807 T1 AT E359807T1
- Authority
- AT
- Austria
- Prior art keywords
- annexin
- modified
- thrombosis
- modified annexin
- prevention
- Prior art date
Links
- 102000000412 Annexin Human genes 0.000 title abstract 9
- 108050008874 Annexin Proteins 0.000 title abstract 9
- 208000007536 Thrombosis Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract 1
- 102000004121 Annexin A5 Human genes 0.000 abstract 1
- 108090000672 Annexin A5 Proteins 0.000 abstract 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 125000003827 glycol group Chemical group 0.000 abstract 1
- 230000023597 hemostasis Effects 0.000 abstract 1
- 239000000710 homodimer Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 108010014806 prothrombinase complex Proteins 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27040201P | 2001-02-21 | 2001-02-21 | |
| US33258201P | 2001-11-21 | 2001-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE359807T1 true ATE359807T1 (de) | 2007-05-15 |
Family
ID=26954268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02721083T ATE359807T1 (de) | 2001-02-21 | 2002-02-21 | Modifizierte annexin-proteine und verhinderung und behandlung von thrombose |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6962903B2 (de) |
| EP (2) | EP1379266B1 (de) |
| JP (3) | JP2004528025A (de) |
| AT (1) | ATE359807T1 (de) |
| AU (1) | AU2002252035A1 (de) |
| DE (1) | DE60219611T2 (de) |
| ES (1) | ES2286247T3 (de) |
| WO (1) | WO2002067857A2 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635676B2 (en) * | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
| US20050222030A1 (en) * | 2001-02-21 | 2005-10-06 | Anthony Allison | Modified annexin proteins and methods for preventing thrombosis |
| US7645739B2 (en) * | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
| US20090291086A1 (en) * | 2001-02-21 | 2009-11-26 | Alavita Pharmaceuticals, Inc. | Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia |
| DE10162434A1 (de) * | 2001-12-18 | 2003-09-25 | November Ag Molekulare Medizin | Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors |
| EP1673108A4 (de) * | 2003-09-09 | 2009-06-03 | Point Biomedical Corp | Verfahren und zusammensetzungen für die ultraschalldarstellung von apoptose |
| AU2005221195B2 (en) * | 2004-03-11 | 2011-05-19 | Alavita Pharmaceuticals, Inc. | Modified annexin proteins and methods for preventing thrombosis |
| EP1755642B1 (de) * | 2004-04-15 | 2010-01-13 | Athera Biotechnologies Ab | Annexin zur prävention von der ruptur des plaques |
| US7393833B2 (en) * | 2005-03-09 | 2008-07-01 | The Board Of Regents Of The University Of Oklahoma | Chimeric proteins with phosphatidylserine binding domains |
| PT2044111E (pt) | 2006-06-21 | 2014-11-12 | Univ Colorado Regents | Abordagem seletiva do fator h do complemento para o tratamento de doenças |
| KR100835879B1 (ko) | 2006-10-10 | 2008-06-09 | 학교법인 한림대학교 | 아넥신 융합 단백질 |
| CN101015686B (zh) * | 2007-02-06 | 2010-05-19 | 中国人民解放军军事医学科学院基础医学研究所 | 一种溶栓药物增效剂及其制备方法 |
| WO2009105231A1 (en) | 2008-02-20 | 2009-08-27 | The General Hospital Corporation | Compositions and methods for treating vascular disorders |
| ES2733902T3 (es) | 2008-02-22 | 2019-12-03 | Annexin Pharmaceuticals Ab | Compuestos y procedimientos para la prevención o tratamiento de reestenosis |
| EP2123258A1 (de) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomen zur Arzneimittelverabreichung |
| EP2350112A4 (de) * | 2008-10-03 | 2013-01-16 | Advanced Proteome Therapeutics Inc | Ortsspezifische n-terminus-proteinmodifikationen und konjugatbildung |
| EP3805758A1 (de) | 2008-12-19 | 2021-04-14 | Medirista Biotechnologies AB | Oxidiertes cardiolipin als neuer proinflammatorischer faktor |
| RS20120461A1 (sr) | 2009-07-02 | 2013-06-28 | Musc Foundation For Research Development | Metode za stimulaciju regeneracije jetre |
| EP2496259B1 (de) | 2009-11-05 | 2017-02-22 | Alexion Pharmaceuticals, Inc. | Behandlung von paroxysmaler nächtlicher hämoglobinurie |
| JP5986990B2 (ja) | 2010-05-14 | 2016-09-06 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート | 改善された補体レセプター２（ｃｒ２）ターゲティング基 |
| MX2012014975A (es) | 2010-06-22 | 2013-03-12 | Univ Colorado Regents | Anticuerpos al fragmento c3d de componente 3 de complemento. |
| JP5584026B2 (ja) * | 2010-07-02 | 2014-09-03 | 株式会社ダイヘン | 抵抗溶接制御方法 |
| CN102690345B (zh) * | 2011-03-24 | 2014-03-19 | 江苏靶标生物医药研究所有限公司 | 人膜联蛋白v变体及其表达、制备和应用 |
| ES2607066T3 (es) | 2011-04-05 | 2017-03-29 | Annexin Pharmaceuticals Ab | Procedimientos terapéuticos y profilácticos, usos y composiciones que comprenden anexina A5 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| WO2016205062A1 (en) * | 2015-06-15 | 2016-12-22 | Shifa Biomedical Corporation | Antithrombotic therapies |
| GB2542391A (en) | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
| CN105906800A (zh) * | 2016-05-06 | 2016-08-31 | 中国科学院长春应用化学研究所 | 一种基因传递系统及其制备方法 |
| AU2017331739A1 (en) | 2016-09-23 | 2019-03-07 | Csl Limited | Coagulation factor binding proteins and uses thereof |
| GB201702144D0 (en) | 2017-02-09 | 2017-03-29 | Annexin Pharmaceuticals Ab | Therapeutic compositions |
| TW202146042A (zh) * | 2020-03-06 | 2021-12-16 | 瑞典商阿斯特捷利康公司 | 用於治療動脈和靜脈血栓形成的協同且靶向的組成物 |
| CN114672483B (zh) * | 2022-05-31 | 2022-09-02 | 上海百力格生物技术有限公司 | 超声法核酸探针制备方法 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| DE3315000A1 (de) | 1983-04-26 | 1984-10-31 | Behringwerke Ag, 3550 Marburg | Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung |
| US5066788A (en) | 1984-09-21 | 1991-11-19 | Boehringer Ingelheim International Gmbh | Blood coagulation inhibiting proteins, processes for preparing them and their uses |
| KR930007434B1 (ko) | 1984-09-21 | 1993-08-10 | 베링거 잉겔하임 인터내셔날 게엠베하 | 혈액응고 억제 단백질 제조방법 |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| CA1265446A (en) | 1985-09-30 | 1990-02-06 | Masahiro Maki | Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component |
| JPH08840B2 (ja) | 1986-11-14 | 1996-01-10 | 興和株式会社 | 抗ｐｃｉモノクローナル抗体、これを用いた抗ｐｃｉの精製法及び免疫学的測定法 |
| DE3643182A1 (de) | 1986-12-18 | 1988-06-30 | Behringwerke Ag | Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4 |
| US4937324A (en) | 1987-02-06 | 1990-06-26 | Zymogenetics, Inc. | Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity |
| JP2660514B2 (ja) | 1987-02-20 | 1997-10-08 | 興和株式会社 | 抗血液凝固作用を有するポリペプチド |
| PT87083B (pt) * | 1987-03-28 | 1992-07-31 | Boehringer Ingelheim Int | Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem |
| US4965251A (en) | 1987-04-03 | 1990-10-23 | The Board Of Regents Of The University Of Washington | Pulse treatment of hemoglobinopathies with erythropoietin |
| DE3737239A1 (de) | 1987-11-03 | 1989-10-12 | Behringwerke Ag | Gentechnische herstellung von anticoagulatorischem protein pp4 |
| ATE124087T1 (de) * | 1988-02-26 | 1995-07-15 | Biogen Inc | Dna-sequenzen, rekombinante dna-moleküle und verfahren zur herstellung von lipocortin iii, iv, v, und vi. |
| US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| EP0409052B1 (de) | 1989-07-15 | 1993-05-12 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Antikoagulanz enthaltendes Mittel |
| EP0409053B1 (de) * | 1989-07-15 | 1993-09-29 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur Reinigung von Annexinen |
| DE3937607A1 (de) | 1989-11-11 | 1991-05-16 | Boehringer Ingelheim Int | Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen |
| DE3942081A1 (de) * | 1989-12-20 | 1991-06-27 | Behringwerke Ag | Mittel zur verbesserung der wiederfindung von annexinen |
| US5627036A (en) * | 1989-12-27 | 1997-05-06 | Boehringer Ingelheim International Gmbh | Use of an anticoagulant as a diagnostic agent |
| US5225537A (en) | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
| CA2081474A1 (en) | 1990-05-08 | 1991-11-09 | Manzer Durrani | Direct spray-dried drug/lipid powder composition |
| JPH06502407A (ja) | 1990-11-02 | 1994-03-17 | ジェネンテク，インコーポレイテッド | 血小板凝集阻害剤 |
| US5360789A (en) * | 1990-11-20 | 1994-11-01 | Kowa Co., Ltd. | Therapeutic agent for skin or corneal disease |
| JP2916947B2 (ja) * | 1990-11-28 | 1999-07-05 | 興和株式会社 | Ｃｐｂ―ｉの安定化方法及び製剤組成物 |
| US5229367A (en) * | 1991-01-21 | 1993-07-20 | Sclavo S.P.A. | Antiinflammatory peptide derived from human lipocortin V |
| EP0538459A4 (en) | 1991-05-09 | 1993-06-16 | The Board Of Regents Of The University Of Washington | Phospholipid-targeted thrombolytic agents |
| US5632986A (en) * | 1991-05-09 | 1997-05-27 | The University Of Washington | Phospholipid-targeted thrombolytic agents |
| JPH051096A (ja) | 1991-06-26 | 1993-01-08 | Kowa Co | 抗血液凝固活性を持つオリゴペプチド |
| EP0646019B9 (de) | 1992-06-09 | 2002-12-18 | Neorx Corporation | Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren |
| AU676483B2 (en) | 1992-07-08 | 1997-03-13 | N.V. Innogenetics S.A. | Polypeptides, derived from endonexin 2, having hepatitis B virus receptor activity and their use in diagnostic and pharmaceutical compositions |
| JP3416912B2 (ja) | 1992-10-08 | 2003-06-16 | 興和株式会社 | 抗血液凝固活性を持つオリゴペプチド |
| JPH0772149A (ja) | 1993-06-30 | 1995-03-17 | Nippon Shinyaku Co Ltd | 肝癌又は肝硬変の診断薬及び診断法 |
| JPH0772147A (ja) | 1993-07-02 | 1995-03-17 | Noboru Kaneko | 抗アネキシンｖ抗体並びに該抗体の製法及び利用 |
| US5849600A (en) * | 1993-11-10 | 1998-12-15 | The Mclean Hospital Corporation | Diagnostic assays for Alzheimer's disease |
| US5968477A (en) * | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
| US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
| WO1995034315A1 (en) | 1994-06-16 | 1995-12-21 | Neorx Corporation | Radiolabeled annexin-galactose conjugates |
| WO1996003655A1 (en) | 1994-07-23 | 1996-02-08 | Boehringer Mannheim Gmbh | Method for the determination of the prethrombotic state |
| DE19541284C2 (de) | 1995-11-06 | 1998-09-24 | Kalden Joachim Robert Prof Dr | Verfahren zur Immunmodulation |
| RU2178307C2 (ru) * | 1995-12-27 | 2002-01-20 | Джинентех Инк. | Производные ов-протеина |
| ES2208942T3 (es) | 1996-07-05 | 2004-06-16 | Philip E. Branton | Proteinas e4 de adenovirus para inducir la muerte celular. |
| JP2001508054A (ja) | 1996-12-30 | 2001-06-19 | イノジェネティックス・ナムローゼ・フェンノートシャップ | ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用 |
| CN1168495C (zh) * | 1997-01-15 | 2004-09-29 | 凤凰药理学公司 | 被修饰的肿瘤坏死因子 |
| US6358508B1 (en) * | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
| US6242570B1 (en) | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
| WO1999002992A1 (en) | 1997-07-11 | 1999-01-21 | The Mount Sinai School Of Medicine Of The City University Of New York | Assays for diagnosis of thrombophilic disease |
| US6511829B1 (en) * | 1997-10-09 | 2003-01-28 | The Regents Of The University Of California | GFP-annexin fusion proteins |
| AU756303B2 (en) | 1997-11-06 | 2003-01-09 | Innogenetics N.V. | Host derived proteins binding HCV: medical, diagnostic and purification use |
| EP1064378A2 (de) | 1998-03-27 | 2001-01-03 | The Board Of Trustees Of The Leland Stanford Junior University | Durch hypoxie-induzierbare humane gene, proteine und deren verwendung |
| US20040002056A1 (en) * | 1998-05-12 | 2004-01-01 | Lorens James B. | Methods of screening for bioactive agents using cells transformed with self-inactivating viral vectors |
| US6169078B1 (en) | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
| AU750414B2 (en) * | 1998-07-13 | 2002-07-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| IL125908A (en) | 1998-08-24 | 2005-05-17 | Nst Neurosurvival Technologies | Peptides and pharmaceutical compositions comprising same |
| WO2000010673A1 (en) | 1998-08-24 | 2000-03-02 | Nst Neurosurvival Technologies Ltd. | Apparatus and method for capturing particles with surface exposure of anionic phospholipids from biological fluids |
| BR9913226A (pt) | 1998-09-01 | 2001-05-22 | Innogenetics Nv | Benzodiazepinas e derivados de benzotiazepinas e peptìdios de hbsag ligados a anexinas, suas composições e uso |
| US6387366B1 (en) | 1998-12-31 | 2002-05-14 | Alg Company | Methods for reducing adverse side effects associated with cellular transplantation |
| CN1125084C (zh) * | 1999-03-12 | 2003-10-22 | 中国科学院上海生物化学研究所 | 一种血栓靶向性溶栓融合蛋白 |
| US6323313B1 (en) * | 1999-06-01 | 2001-11-27 | The University Of Washington | Annexin derivative with endogenous chelation sites |
| US6645465B2 (en) | 1999-08-06 | 2003-11-11 | Michigan, University Of The Regents | Annexin proteins and autoantibodies as serum markers for cancer |
| CA2444483A1 (en) * | 2001-04-26 | 2002-11-07 | Board Of Regents, The University Of Texas System | Diagnostic imaging compositions, their methods of synthesis and use |
-
2002
- 2002-02-21 WO PCT/US2002/005079 patent/WO2002067857A2/en not_active Ceased
- 2002-02-21 JP JP2002567229A patent/JP2004528025A/ja not_active Withdrawn
- 2002-02-21 EP EP02721083A patent/EP1379266B1/de not_active Expired - Lifetime
- 2002-02-21 DE DE60219611T patent/DE60219611T2/de not_active Expired - Lifetime
- 2002-02-21 AU AU2002252035A patent/AU2002252035A1/en not_active Abandoned
- 2002-02-21 US US10/080,370 patent/US6962903B2/en not_active Expired - Fee Related
- 2002-02-21 ES ES02721083T patent/ES2286247T3/es not_active Expired - Lifetime
- 2002-02-21 EP EP07106226A patent/EP1839670A3/de not_active Withdrawn
- 2002-02-21 AT AT02721083T patent/ATE359807T1/de not_active IP Right Cessation
-
2005
- 2005-04-20 US US11/110,306 patent/US7407475B2/en not_active Expired - Fee Related
-
2008
- 2008-05-27 JP JP2008137728A patent/JP2008263991A/ja active Pending
-
2010
- 2010-04-01 JP JP2010084883A patent/JP2010189405A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1379266B1 (de) | 2007-04-18 |
| EP1379266A2 (de) | 2004-01-14 |
| DE60219611D1 (de) | 2007-05-31 |
| JP2010189405A (ja) | 2010-09-02 |
| AU2002252035A1 (en) | 2002-09-12 |
| US20030166532A1 (en) | 2003-09-04 |
| EP1839670A3 (de) | 2009-11-11 |
| US6962903B2 (en) | 2005-11-08 |
| JP2004528025A (ja) | 2004-09-16 |
| US7407475B2 (en) | 2008-08-05 |
| DE60219611T2 (de) | 2007-12-27 |
| WO2002067857A2 (en) | 2002-09-06 |
| EP1839670A2 (de) | 2007-10-03 |
| ES2286247T3 (es) | 2007-12-01 |
| US20050197295A1 (en) | 2005-09-08 |
| JP2008263991A (ja) | 2008-11-06 |
| EP1379266A4 (de) | 2004-05-06 |
| WO2002067857A3 (en) | 2002-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60219611D1 (de) | Modifizierte annexin-proteine und verhinderung und behandlung von thrombose | |
| DE60126249D1 (de) | Heterologe expression von neisseria proteine | |
| ES2333598T5 (es) | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. | |
| TR199801390T2 (xx) | Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler | |
| DK1329458T3 (da) | Peptider som sænker blodglucoseniveauer | |
| DE60019777D1 (de) | Zusammensetzung enthaltend caseinprotein und molkenprotein | |
| DE60042403D1 (de) | Modifizierte faktor viia proteine | |
| TR199802421T2 (xx) | Doku yenilenmesini d�zenleyen maddeler. | |
| ATE113475T1 (de) | Hybride prokoagulierende proteine. | |
| ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| PT1107996E (pt) | Anticorpos humanos anti-factor ix/ixa | |
| ATE234111T1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
| ATE273388T1 (de) | Veränderte menschliche c3-proteine | |
| NO993424D0 (no) | Fremgangsmåte til selektiv nedbrytning av melkeprotein i naervaer av andre melkeproteiner | |
| SE9904377D0 (sv) | Pharmaceutical combinations | |
| ATE173014T1 (de) | Afamin: ein menschliches serum albumin ähnliches protein | |
| DE60206289D1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
| TR200002101T2 (tr) | Dondurulmuş gıda ürünü. | |
| DE60015988D1 (de) | Modifizierung von schaumeigenschaften von proteinen | |
| WO2000048625A3 (en) | Inhibitors for use in hemostasis and immune function | |
| WO2005086955A3 (en) | Modified annexin proteins and methods for preventing thrombosis | |
| ATE235915T1 (de) | Behandlung von hämorrhagischem virusfieber mit protein c | |
| MXPA03000979A (es) | Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas. | |
| WO2003027251A3 (en) | Novel molecules of the pyrin domain protein family and uses thereof | |
| ATE226591T1 (de) | Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |